The Fate of an Amazonian Savanna: Government Land-Use Planning Endangers Sustainable Development in Amapá, the Most Protected Brazilian State

Although Amapa´ is the most protected Brazilian state, the same level of protection does not extend to its savannas. These are currently suffering increased pressure from threats including large-scale agriculture, particularly the expansion of soybean plantations. In September 2016, the Government of Amapa´ presented a zoning proposal (Zoneamento Socioambiental do Cerrado [ZSC]) that reserves most of the savannas for agricultural activities. Here, we outline how the methodology employed is flawed because it does not include fauna surveys, evaluations of ecosystem services or an assessment of the social importance of the savannas. The ZSC authors admit that, contrary to Brazilian legislation, the zoning was carried out with the single intention of increasing agriculture production. Current knowledge indicates that Amapa´’s savannas are rich in biodiversity, including endemic and threatened species, and are also home to a rich culture of traditional populations. These savannas are important providers of ecosystem services that, if intact, could represent around US$ 1.52 billion annually. We hold that the ZSC should be reformulated, with fair participation of stakeholders, in accordance with Brazil’s legal requirements. At least 30% of the savannas should be protected, local family farming should be supported, and the rights of traditional peoples must now be assured through recognition of their land rights

The Fate of an Amazonian Savanna: Government Land-Use Planning Endangers Sustainable Development in Amapá, the Most Protected Brazilian State

Although Amapa´ is the most protected Brazilian state, the same level of protection does not extend to its savannas. These are currently suffering increased pressure from threats including large-scale agriculture, particularly the expansion of soybean plantations. In September 2016, the Government of Amapa´ presented a zoning proposal (Zoneamento Socioambiental do Cerrado [ZSC]) that reserves most of the savannas for agricultural activities. Here, we outline how the methodology employed is flawed because it does not include fauna surveys, evaluations of ecosystem services or an assessment of the social importance of the savannas. The ZSC authors admit that, contrary to Brazilian legislation, the zoning was carried out with the single intention of increasing agriculture production. Current knowledge indicates that Amapa´’s savannas are rich in biodiversity, including endemic and threatened species, and are also home to a rich culture of traditional populations. These savannas are important providers of ecosystem services that, if intact, could represent around US$ 1.52 billion annually. We hold that the ZSC should be reformulated, with fair participation of stakeholders, in accordance with Brazil’s legal requirements. At least 30% of the savannas should be protected, local family farming should be supported, and the rights of traditional peoples must now be assured through recognition of their land rights

Biodiversity, threats and conservation challenges in the Cerrado of Amapá, an Amazonian savanna

An Amazonian savanna in northern Brazil known as the Cerrado of Amapá is under imminent threat from poor land-use planning, the expansion of large-scale agriculture and other anthropogenic pressures. These savannas house a rich and unique flora and fauna, including endemic plants and animals. However, the area remains under-sampled for most taxa, and better sampling may uncover new species. We estimate that only ∼9.16% of these habitats have any kind of protection, and legislative changes threaten to further weaken or remove this protection. Here we present the status of knowledge concerning the biodiversity of the Cerrado of Amapá, its conservation status, and the main threats to the conservation of this Amazonian savanna. To secure the future of these unique and imperilled habitats, we suggest urgent expansion of protected areas, as well as measures that would promote less-damaging land uses to support the local population. Copyright © 2017 Karen Mustin et al

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≥ II, EF ≤35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation

Alirocumab and cardiovascular outcomes after acute coronary syndrome

BACKGROUN

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

BACKGROUN